Sorry, you need to enable JavaScript to visit this website.
For the short-term, non-continuous treatment of mild to moderate eczema (atopic dermatitis) not well controlled on topical therapies in people 12 and older without weakened immune systems or when those therapies are not recommended.

Using a topical cream

using a topical cream

OPZELURA is not an ointment. It is a non-steroidal cream that can be applied directly to the areas of the skin where you have mild to moderate eczema. OPZELURA can be used on its own to help clear skin and significantly reduce itch. It was studied across a range of skin tones and can be used where you have eczema, even sensitive areas like the face.

How to use OPZELURA:

Apply OPZELURA directly to your eczema as directed by your healthcare provider

How much and how often to apply:
  • Apply a thin layer of OPZELURA cream twice daily to affected areas of the skin.
  • Use OPZELURA on up to 20% of your body as directed by your healthcare provider.
    • As a tip, 1 handprint = 1% of your body surface area.
  • Use as directed by your healthcare provider if eczema symptoms return.
  • Do not use more than one 60-gram tube per week.
  • Stop using OPZELURA once signs and symptoms (e.g., itch and rash that may appear red,
    purple, or gray) of eczema have resolved. If signs and symptoms do not improve within 8
    weeks, patients should be re-examined by their healthcare provider.
Where to use:
  • Apply OPZELURA directly to the affected areas of the skin.
  • Can be applied on any areas where you have eczema, even sensitive ones like the face.
    OPZELURA is for use on the skin only. Do not use in your eyes, mouth or vagina.
Important information about using OPZELURA:
  • Use OPZELURA exactly as your healthcare provider tells you.
  • Wash your hands after applying OPZELURA (unless your hands are being treated). If
    someone is applying OPZELURA for you, they should wash their hands after applying.
  • Be sure to talk to your healthcare provider if you have any questions or concerns about
    OPZELURA, and to report any side effects.
Download the OPZELURA
patient brochure
 

GET
IncyteCARES
SUPPORT

Get help with coverage info, support or
assistance you may need for treatment.

 

Stay In
The Know

Get information and updates about
OPZELURA sent directly to you.

IMPORTANT SAFETY INFORMATION AND INDICATION
Indication and Usage

OPZELURA is a prescription medicine
used on the skin (topical) for
short-term and non-continuous
treatment of mild to moderate
eczema (atopic dermatitis)
in non-immunocompromised people
12 and older whose disease is not
well controlled with topical
prescription therapies or when those
therapies are not recommended.

The use of OPZELURA along with
therapeutic biologics for atopic
dermatitis, other JAK inhibitors, or
strong immunosuppressants such
as azathioprine or cyclosporine is
not recommended.

Important Safety Information

OPZELURA cream is for use on the skin only. Do not use OPZELURA cream, in your eyes, mouth or vagina.

OPZELURA may cause serious side effects, including:

Serious Infections: OPZELURA cream contains ruxolitinib. Ruxolitinib belongs to a class of medicines called Janus kinase (JAK) inhibitors. JAK inhibitors are medicines that affect your immune system. JAK inhibitors can lower the ability of your immune system to fight infections. Some people have had serious infections while taking JAK inhibitors by mouth, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized or died from these infections. Some people have had serious infections of their lungs while taking OPZELURA. Your healthcare provider should watch you closely for signs and symptoms of TB during treatment with OPZELURA.

OPZELURA should not be used in people with an active, serious infection, including localized infections. You should not start using OPZELURA if you have any kind of infection unless your healthcare provider tells you it is okay. You may be at a higher risk of developing shingles (herpes zoster) while using OPZELURA.

Increased risk of death from all causes, including sudden cardiac death, has happened in people taking JAK inhibitors by mouth.

Cancer and immune system problems: OPZELURA may increase your risk of certain cancers by changing the way your immune system works. Some people have had lymphoma and other cancers while taking JAK inhibitors by mouth, especially if they are a current or past smoker. Some people have had skin cancers while taking OPZELURA. Your healthcare provider will regularly check your skin during your treatment with OPZELURA.

There is an increased risk of major cardiovascular events such as heart attack, stroke or cardiac death in people with cardiovascular risk factors and who are current or past smokers while using JAK inhibitors to treat inflammatory conditions.

Blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen in some people taking OPZELURA. This may be life-threatening.

Low blood cell counts: OPZELURA may cause low platelet counts (thrombocytopenia), low red blood cell counts (anemia), and low white blood cell counts (neutropenia). If needed, your healthcare provider will do a blood test to check your blood cell counts during your treatment with OPZELURA and may stop your treatment if signs or symptoms of low blood cell counts happen.

Cholesterol increases: Cholesterol increase has happened in people when ruxolitinib is taken by mouth. Tell your healthcare provider if you have high cholesterol or triglycerides.

Before starting OPZELURA, tell your healthcare provider if you:

  • have an infection, are being treated for one, or have an infection that keeps coming back
  • have diabetes, chronic lung disease, HIV, or a weak immune system
  • have or had TB, or have been in close contact with someone with TB
  • have had shingles (herpes zoster) or hepatitis B or C
  • live, have lived in, or have traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections. These infections may happen or become more severe if you use OPZELURA. Ask your healthcare provider if you do not know if you have lived in an area where these infections are common.
  • think you have an infection or have symptoms of an infection such as:
  • fever, sweating, or chills
  • muscle aches
  • cough or shortness of breath
  • blood in your phlegm
  • weight loss
  • warm, red, or painful skin or sores on your body
  • diarrhea or stomach pain
  • burning when you urinate or urinating more often than usual
  • feeling very tired
  • have ever had any type of cancer, or are a current or past smoker
  • have had blood clots in the veins of your legs or lungs in the past
  • have high cholesterol or triglycerides
  • have or have had low white or red blood cell counts
  • are pregnant or plan to become pregnant. It is not known if OPZELURA will harm your unborn baby. There is a pregnancy exposure registry for individuals who use OPZELURA during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. If you become exposed to OPZELURA during pregnancy, you and your healthcare provider should report exposure to Incyte Corporation at 1-855-463-3463.
  • are breastfeeding or plan to breastfeed. It is not known if OPZELURA passes into your breast milk. Do not breastfeed during treatment with OPZELURA and for about 4 weeks after the last dose.

After starting OPZELURA:

  • Call your healthcare provider right away if you have any symptoms of an infection. OPZELURA can make you more likely to get infections or make worse any infections that you have.
  • Get emergency help right away if you have any symptoms of a heart attack or stroke while using OPZELURA, including:
  • discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back
  • severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
  • pain or discomfort in your arms, back, neck, jaw, or stomach
  • shortness of breath with or without chest discomfort
  • breaking out in a cold sweat
  • nausea or vomiting
  • feeling lightheaded
  • weakness in one part or on one side of your body
  • slurred speech
  • Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with OPZELURA, including: swelling, pain or tenderness in one or both legs, sudden, unexplained chest or upper back pain, or shortness of breath or difficulty breathing.
  • Tell your healthcare provider right away if you develop or have worsening of any symptoms of low blood cell counts, such as: unusual bleeding, bruising, tiredness, shortness of breath or fever.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of OPZELURA include: pain or swelling in your nose or throat (nasopharyngitis), diarrhea, bronchitis, ear infection, increase in a type of white blood cell (eosinophil) count, hives, inflamed hair pores (folliculitis), swelling of the tonsils (tonsillitis), and runny nose (rhinorrhea).

These are not all of the possible side effects of OPZELURA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Incyte Corporation at 1-855-463-3463.

Please see the Full Prescribing Information, including Boxed Warning, and Medication Guide for OPZELURA.